ArticleJournal of virology2025
T-cell receptor/CD28-targeted immunotherapeutics selectively drive naive T-cell expansion to generate functional HIV-specific responses.
April L Mueller, Sara Lamcaj, Scott Garforth, Christopher Hiner, Darien Woodley, Kitt Paraiso, Tian Mi, Simon Low, Ben Youngblood, Steven C Almo and 1 more
Abstract read
In one paragraphArticle in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
April L MuellerDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.ORCID 0000-0002-2134-5134 Sara LamcajDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Scott GarforthDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Christopher HinerDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Darien WoodleyDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
Kitt ParaisoCellecta, Inc., Mountain View, California, USA.
Tian MiDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Simon LowCue Biopharma, Boston, Massachusetts, USA.
Ben YoungbloodDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Harris GoldsteinDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.ORCID 0000-0003-0543-6025 Funding
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI Ulrich Steidl · 1985 to 2026
$111.2MPatient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Vilma Gabbay · 2017 to 2026
$28.3McGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0MMedical Scientist Training ProgramT32GM149364 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Myles H. Akabas · 2023 to 2026
$7.5MTraining in HIV/AIDS Pathogenesis; Basic and Translational ResearchT32AI007501 · NIAID · YESHIVA UNIVERSITY · PI PRASAD, VINAYAKA R. · 1995 to 2024
$6.6MTask Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1MAmplifying and Redirecting CMV-specific CD8 T cells to provide sustained control of HIV infectionR01AI172607 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI ALMO, STEVEN C., GOLDSTEIN, HARRIS · 2022 to 2025
$4.4MNovel Biologics Designed to Mobilize HIV-specific CTL for Sustained HIV RemissionR01AI145024 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI ALMO, STEVEN C., GOLDSTEIN, HARRIS · 2019 to 2023
$4.1MDeveloping and evaluating cell-specific lentivectors capable of selective in vivo generation of anti-HIV T cells to cure HIVR01AI174275 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI HARRIS GOLDSTEIN · 2024 to 2026
$2.2MNCI NIH HHS P30 CA013330NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS 75N93023D00005NIAID NIH HHS P30 AI124414NIAID NIH HHS R01 AI145024NIAID NIH HHS R01 AI172607NIAID NIH HHS R01 AI174275NIAID NIH HHS T32 AI007501NIDA NIH HHS 75N95020D00005NIGMS NIH HHS T32 GM149364NIH HHS 1R01AI145024,1R01AI174275,5R01AI172607,P30AI124414NIH HHS 5T32AI007501NIH HHS 5T32GM149364ORFDO NIH HHS 75N99020D00005
6 · The paper itselfAbstract
Adoptive cell transfer (ACT), a promising immunotherapeutic approach, treats viral infections or cancer by IMPORTANCE: Adoptive transfer of
Indexed as
CD28 AntigensCD8-Positive T-LymphocytesHIV InfectionsReceptors, Antigen, T-CellDendritic CellsEpitopes, T-LymphocyteHIV-1HumansImmunotherapyImmunotherapy, AdoptiveLymphocyte ActivationMART-1 AntigenCD28 AntigensEpitopes, T-LymphocyteMART-1 AntigenReceptors, Antigen, T-CellHIVimmunologyT cells
Identifiers
PMID40762498
PMCPMC12456003
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390